Ingenia Therapeutics
CompanyUnited StatesFounded 2018
Ingenia Therapeutics develops one asset, in phase 1 (IGT-303 in chronic kidney disease). Mostly antibody; based in the United States, founded in 2018.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 1
- Signal
Pipeline
1Phase 1, Antibody, chronic kidney disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Signals2
- Similar companies6